What is psoriasis

Overview and Definition

Psoriasis is a chronic, non-contagious autoimmune inflammatory skin disease that causes the body to produce new skin cells too quickly. Normally, skin cells mature and shed approximately every 28-30 days. In psoriasis, this process accelerates dramatically, with new cells being produced every 3-7 days, causing them to accumulate into thick, raised, inflamed patches called plaques. These plaques are typically covered with silvery-white scales and can be itchy, painful, and prone to bleeding when scratched. The condition affects people across all ages, though it most commonly emerges during young adulthood or middle age.

Causes and Pathophysiology

Psoriasis results from a combination of genetic predisposition and environmental triggers. Approximately 10% of the population carries genes associated with psoriasis, but only 2-3% actually develop the condition, suggesting that genetic vulnerability alone is insufficient. Research indicates that the immune system plays a central role, with T-cells mistakenly attacking skin cells, triggering inflammation and accelerated cell turnover. Key triggers include: streptococcal infections (with studies showing 26-41% of psoriasis cases preceded by strep throat), psychological stress (linked to flare-ups in 30-88% of patients), skin injuries or trauma (known as the Köbner phenomenon), certain medications including beta-blockers and lithium (affecting 25-50% of susceptible individuals), alcohol consumption (particularly in men, increasing risk 1.5-2 times), smoking (which doubles psoriasis risk), and obesity (associated with earlier onset and severity). Climate also plays a role, with 80% of patients reporting improvement during summer months due to increased UV exposure.

Types of Psoriasis

Psoriasis manifests in several distinct forms. Plaque psoriasis, comprising 90% of cases, features well-defined, raised patches with silvery scales, most commonly appearing on extensor surfaces like elbows and knees. Guttate psoriasis, accounting for 8% of cases, presents as small, droplet-shaped lesions typically following a streptococcal infection, with an average onset of 2-3 weeks after infection. Inverse psoriasis appears in skin folds (armpits, groin, under breasts) as smooth, inflamed patches affecting approximately 3-7% of psoriasis patients. Pustular psoriasis, a severe form comprising 1-2% of cases, features pus-filled blisters and poses greater systemic risks. Erythrodermic psoriasis, affecting less than 1% of patients, involves widespread inflammation covering more than 90% of the body surface, constituting a medical emergency requiring hospitalization. Nail psoriasis occurs in 50% of psoriasis patients, causing pitting, discoloration, and thickening.

Symptoms and Impact on Daily Life

Symptoms vary greatly depending on type and severity. Most commonly, patients experience itching (affecting 71-99% of psoriasis patients), burning, and pain in affected areas. Plaques can crack and bleed, and the scales can be difficult to manage and emotionally distressing due to visibility and social stigma. Beyond physical symptoms, psychological impacts are substantial: depression occurs in 10-15% of psoriasis patients, anxiety in 15-30%, and social isolation is common due to embarrassment about appearance. Approximately 25% of patients report that psoriasis negatively impacts their work productivity or causes them to miss work days. Joint pain from associated psoriatic arthritis affects 30% of psoriasis patients, potentially limiting mobility and exercise capacity. Sleep disturbance affects 47-88% of patients due to itching and discomfort.

Diagnosis and Medical Evaluation

Diagnosis is typically clinical, based on examination of characteristic plaques and patient history. Dermatologists may perform a skin biopsy in unclear cases, revealing hyperkeratosis, parakeratosis, and elongated rete ridges under microscopy. Blood tests may assess for related conditions or comorbidities, as psoriasis patients have higher rates of metabolic syndrome, cardiovascular disease, and type 2 diabetes. Dermatologists assess severity using the Psoriasis Area Severity Index (PASI), scoring 0-72, with scores above 10 typically considered moderate to severe disease. Approximately 70% of patients have mild psoriasis (affecting less than 10% of body surface area), while 20% have moderate psoriasis, and 10% have severe disease.

Common Misconceptions and Myths

A widespread misconception is that psoriasis is contagious; it is not. The condition cannot be transmitted through contact, sharing dishes, towels, or any form of physical contact. Many patients report social rejection based on this false belief, compounding psychological distress. Another common myth is that psoriasis is purely a skin condition; mounting evidence shows psoriasis is a systemic disease with significant metabolic, cardiovascular, and immunological implications. Patients with moderate to severe psoriasis have increased cardiovascular mortality risk of 20-50%, comparable to the risk in smokers. A third misconception is that psoriasis is caused by poor hygiene or stress alone; while stress and hygiene can influence symptoms, psoriasis is fundamentally an autoimmune condition requiring medical intervention. Some patients believe that sunbathing always helps; while controlled UV exposure benefits many patients, excessive sun exposure without protection can damage skin and increase skin cancer risk, with psoriasis patients already having slightly elevated melanoma risk.

Treatment Options and Management Strategies

Treatment approaches range from topical to systemic to biologic therapies, selected based on severity, patient preference, and comorbidities. Topical treatments form first-line therapy for mild to moderate psoriasis: topical corticosteroids (typically used for 2-4 weeks, with response rates of 60-80%), vitamin D analogues (calcipotriene), tacrolimus, and retinoids (tretinoin). Phototherapy (light therapy) uses UVB or PUVA (psoralen plus UVA) exposure in controlled medical settings, with studies showing 75% of patients achieving significant improvement after 15-25 sessions over 6-10 weeks. Systemic medications for moderate to severe psoriasis include methotrexate, acitretin, and cyclosporine, each with specific efficacy rates and side effect profiles requiring careful monitoring. Biologic therapies represent the most advanced option, including TNF-alpha inhibitors (infliximab, etanercept, adalimumab), IL-12/23 inhibitors (ustekinumab), and newer IL-17 and IL-23 inhibitors (secukinumab, ixekizumab, risankizumab), which demonstrate PASI 75 response rates (75% improvement) in 60-90% of patients depending on the agent. Lifestyle modifications including stress reduction, smoking cessation, limiting alcohol, maintaining healthy weight, and regular exercise complement medical therapy. Moisturizing with emollients containing ceramides, hyaluronic acid, or glycerin applied within 3 minutes of bathing improves barrier function and reduces dryness in 70-85% of patients.

Practical Considerations and Living with Psoriasis

Successful psoriasis management requires a partnership between patient and healthcare provider. Patients should track triggers in a diary to identify personal patterns, as triggers vary significantly between individuals. Stress management techniques including meditation, yoga, or cognitive behavioral therapy reduce flare frequency in 40-50% of patients. Dietary modifications, though not curative, may help some patients—Mediterranean diet and omega-3 supplementation show modest benefits in preliminary studies, while processed foods and excessive alcohol should be avoided. Workplace accommodations may be necessary for severe cases affecting hands or visible areas. Support groups and counseling address psychological impacts, with therapy reducing depression and anxiety in 30-50% of participants. Patients should schedule regular dermatology follow-ups every 3-6 months to assess treatment efficacy and adjust therapy as needed. Sun protection is important: while controlled UV exposure helps some patients, uncontrolled sun exposure increases skin cancer risk, and patients should use SPF 30+ sunscreen on non-affected areas.